Evusheld: A long-acting antibody combination for the prevention of COVID-19 in high-risk individuals
Category: Analytical/Test
Developers: Vanderbilt University
Co-Developers: Vanderbilt University Medical Center; AstraZeneca
United States
Product Description:The immune systems of the immunocompromised often fail to generate proper antibodies in response to a vaccination, leaving this large sub-population of people exposed to infection. Evusheld is an FDA EUA-approved antibody medicine for COVID-19 that is delivered via intramuscular injection and provides lifesaving protection to this highly vulnerable group.
Developers: Vanderbilt University
Co-Developers: Vanderbilt University Medical Center; AstraZeneca
United States
Product Description:The immune systems of the immunocompromised often fail to generate proper antibodies in response to a vaccination, leaving this large sub-population of people exposed to infection. Evusheld is an FDA EUA-approved antibody medicine for COVID-19 that is delivered via intramuscular injection and provides lifesaving protection to this highly vulnerable group.
Evusheld Photo